SCHEMBL12643289

SCHEMBL12643289

CCCCc1csc(C(C)C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.43
DRD2 P14416 2/20 0.39
HTR2A P28223 1/20 0.39
HRH1 P35367 1/20 0.39
KCNH2 Q12809 1/20 0.36
NOS2 P35228 1/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
ALDH1A1 P00352 1/20 0.34
ADORA2A P29274 1/20 0.33
HTR6 P50406 1/20 0.33
ADRB2 P07550 2/20 0.32
ADRB1 P08588 2/20 0.32
ADRB3 P13945 2/20 0.32
TLR7 Q9NYK1 1/20 0.31
CYP3A4 P08684 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
NMT1 P30419 1/20 0.31
PTPRB P23467 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15000428 0.95 KCNH2 (0.43) SLC6A3DRD2HTR2AHRH1KCNH2
SCHEMBL10058000 0.89 SLC6A3 (0.45) SLC6A3DRD2HTR2AHRH1ALDH1A1
SCHEMBL14638829 0.81 SLC6A3 (0.45) SLC6A3DRD2HTR2AHRH1ALDH1A1
SCHEMBL2819185 0.80 SLC6A3 (0.47) SLC6A3DRD2HTR2AHRH1ESR1
SCHEMBL15591337 0.79 SLC6A3 (0.44) SLC6A3DRD2HTR2AHRH1ALDH1A1
SCHEMBL13045053 0.79 SLC6A3 (0.44) SLC6A3DRD2HTR2AHRH1NOS2
SCHEMBL7179624 0.79 SLC6A3 (0.44) SLC6A3DRD2HTR2AHRH1ALDH1A1
Hydrochloric Acid SCHEMBL15544889 0.78 SLC6A3 (0.43) SLC6A3DRD2HTR2AHRH1ALDH1A1
SCHEMBL6222760 0.77 FDPS (0.38) SLC6A3ESR1ESR2MEN1KMT2A
SCHEMBL6439079 0.77 HRH4 (0.39) SLC6A3DRD2HTR2AHRH1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9822147-B2 Methods of treating ophthalmic diseases using NPR-B agonists SHIRE ORPHAN THERAPIES GMBH (DE) 2017-11-21 US disclosed
WO-2011075471-A2 NOVEL NPR-B AGONISTS AND METHODS OF USE FOR THE TREATMENT OF C-TYPE NATRIURETIC PEPTIDE-MEDIATED DISORDERS ALCON RESEARCH, LTD. (US) 2011-06-23 WO disclosed